Moreover, FLT3, TP53, and NRAS mutations are classified as driver oncogenes in AML, and co-occurring mutations in those genes have been associated not only with resistance but also with metabolic adaptations [28,35,36,37]. Here, TP53 is linked to acute myeloid leukemia.